Related Experiment Video
Updated: Jul 19, 2026
08:03
Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
Stem cell therapy enhances electrical viability in myocardial infarction
William R Mills1, Niladri Mal, Matthew J Kiedrowski
1The Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, Cleveland, OH 44109, USA.
Journal of Molecular and Cellular Cardiology
|October 31, 2006
Summary
Mesenchymal stem cell (MSC) therapy improved cardiac function and reduced arrhythmia risk after myocardial infarction (MI), unlike skeletal myoblast (SKMB) therapy which increased risk. MSCs enhanced electrical viability and integrated better, explaining the difference.
Area of Science:
- Regenerative Medicine
- Cardiovascular Biology
- Biomedical Engineering
Background:
- Cell therapy for myocardial infarction (MI) shows promise but carries an increased risk of arrhythmias.
- The mechanisms underlying this increased arrhythmia risk are not well understood.
- Electrical viability in the infarct and border zones may influence arrhythmia vulnerability.
Purpose of the Study:
- To investigate the impact of skeletal myoblast (SKMB) and mesenchymal stem cell (MSC) therapy on arrhythmia risk post-MI.
- To determine if cell engraftment, electrical viability, and connexin expression correlate with arrhythmia inducibility.
- To compare the effects of intramyocardial SKMB injection versus intravenous MSC infusion.
Main Methods:
- Rats underwent LAD ligation to induce MI, followed by intramyocardial SKMB injection, intravenous MSC infusion, or saline control.
- Cardiac function (shortening fraction) was assessed one month post-MI.
- Optical mapping was used to evaluate electrical viability, impulse propagation, and arrhythmia inducibility.
- Cell engraftment patterns and connexin expression were analyzed.
Main Results:
- Both SKMB and MSC therapies improved cardiac function compared to MI alone.
- SKMB therapy significantly increased arrhythmia inducibility, while MSC therapy tended to decrease it.
- MSC therapy preserved electrical viability and impulse propagation in the border zone, unlike SKMB therapy.
- MSCs showed homogeneous engraftment and expressed connexins, whereas SKMBs formed clusters lacking connexins.
Conclusions:
- MSC therapy offers a potentially safer approach for cell-based treatment of MI, improving cardiac function while reducing arrhythmia risk.
- SKMB therapy, despite improving cardiac function, significantly increases arrhythmia risk due to poor integration and lack of electrical coupling.
- Electrical viability, diffuse engraftment, and connexin expression are critical factors determining arrhythmia vulnerability after cell therapy for MI.
